Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc. 康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION PROPOSED DISPOSAL OF A SHARES BY SHAREHOLDERS

This announcement is made by CanSino Biologics Inc. (the "Company") pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

PROPOSED DISPOSAL OF A SHARES BY SHAREHOLDERS

The Company has been informed by Tianjin Qianyi Enterprise Management Partnership (Limited Partnership) (天津千益企業管理合夥企業(有限合夥)) ("Tianjin Qianyi"), Tianjin Qianrui Enterprise Management Partnership (Limited Partnership) (天津千睿企業管理合夥企業(有限合夥)) ("Tianjin Qianrui") and Tianjin Qianzhi Enterprise Management Partnership (Limited Partnership) (天津千智企業管理合夥企業(有限合夥)) ("Tianjin Qianzhi", together with Tianjin Qianyi and Tianjin Qianrui, the "Employee Incentive Platforms") that they intend to dispose of certain A shares of the Company (the "A Shares") during the period as stipulated below through centralized bidding and block trading (the "Proposed Disposal"), which shall be subject to percentage restrictions under the applicable laws of the People's Republic of China. The Proposed Disposal shall be implemented within 6 months after the 15 trading days of publication of the Proposed Disposal through centralized bidding, and within 6 months after the 3 trading days of publication of the Proposed Disposal through block trading.

The total number of A Shares to be disposed of by the Employee Incentive Platforms through centralized bidding and block trading shall be no more than 4,910,000 A Shares, representing approximately 1.98% of the total issued shares of the Company. The details of the Proposed Disposal are set out below:

Employee Incentive Platform	Maximum number of A Shares to be disposed of by the Employee Incentive Platform	Maximum percentage of shareholding in total issued shares of the Company to be disposed by the Employee Incentive Platform	Method of the Proposed Disposal	Period of the Proposed Disposal by bidding	Price range for the Proposed Disposal	Source of A Shares for the Proposed Disposal	Reason for the Proposed Disposal
Tianjin Qianyi	Up to 2,680,000 A Shares	Up to 1.08%	By bidding: up to 2,680,000 A Shares By block trading: up to 2,680,000 A Shares	September 5, 2023 to March 4, 2024	Based on market price	A Shares obtained before the Company's initial public offering of A Shares and listing on the Sci-Tech Innovation Board of Shanghai Stock Exchange	Financial requirement and arrangement
Tianjin Qianrui	Up to 1,500,000 A Shares	Up to 0.61%	By bidding: up to 1,500,000 A Shares By block trading: up to 1,500,000 A Shares	September 5, 2023 to March 4, 2024	Based on market price	A Shares obtained before the Company's initial public offering of A Shares and listing on the Sci-Tech Innovation Board of Shanghai Stock Exchange	Financial requirement and arrangement
Tianjin Qianzhi	Up to 730,000 A Shares	Up to 0.30%	By bidding: up to 730,000 A Shares By block trading: up to 730,000 A Shares	September 5, 2023 to March 4, 2024	Based on market price	A Shares obtained before the Company's initial public offering of A Shares and listing on the Sci-Tech Innovation Board of Shanghai Stock Exchange	Financial requirement and arrangement

Dr. Tao ZHU is the sole general partner of each of the Employee Incentive Platforms, therefore he is able to control the voting rights attached to the shares held by the Employee Incentive Platforms. Pursuant to a concert party agreement, Dr. Xuefeng YU, Dr. Tao ZHU, Dr. Dongxu QIU and Dr. Helen Huihua MAO (the "Controlling Shareholders") have undertaken to, among other things, vote (and procure the entities held by them if any to vote) unanimously for any resolutions proposed at any shareholders' meeting of the Company. As of the date of this announcement, the Controlling Shareholders collectively held approximately 31.19% of the shareholding interest of the Company (including the shareholding interest held by the Employee Incentive Platforms). In the event that the Employee Incentive Platforms dispose of over 1.19% of the shareholding interest of the Company, Dr. Xuefeng YU, Dr. Tao ZHU, Dr. Dongxu QIU and Dr. Helen Huihua MAO will cease to be the controlling shareholders of the Company under the Listing Rules.

The Employee Incentive Platforms will decide whether to carry out the Proposed Disposal after taking into account various factors, including market conditions and share price of the Company. The Company will make further announcements in relation to the Proposed Disposal and comply with all applicable requirements under the Listing Rules as and when necessary.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 15, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.